Plasma SAA1 Levels in Predicting Response to Radiotherapy-induced Oral Mucositis

Launched by NANFANG HOSPITAL, SOUTHERN MEDICAL UNIVERSITY · Mar 6, 2024

Keywords

ClinConnect Summary

This clinical trial is studying whether levels of a protein called serum amyloid A1 (SAA1) in the blood can help predict how patients with nasopharyngeal carcinoma and other head and neck cancers will respond to radiotherapy, particularly in terms of a common side effect known as radiotherapy-induced oral mucositis (RIOM). Oral mucositis can cause painful inflammation in the mouth, making it difficult for patients to eat and drink, which can affect their overall treatment experience and recovery. Researchers want to see if measuring SAA1 levels can help identify patients at risk for this condition early on, allowing for better management and care.

To be eligible to join this trial, participants must be over 18 years old, have a confirmed diagnosis of nasopharyngeal carcinoma or another head and neck tumor, and need radiotherapy as part of their treatment. They should also be in relatively good health, with a performance score indicating they can carry out daily activities. If they decide to participate, they will provide blood samples for testing, and the study aims to gather information that could improve how patients manage side effects from their cancer treatment in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Over 18 years of age.
• • Voluntarily sign informed consent.
• • The pathological diagnosis was nasopharyngeal carcinoma, head and neck tumor.
• • Need to be treated with radiotherapy.
• • ECOG PS Score: 0/1.
• Exclusion Criteria:
• • There are contraindications to radiotherapy.
• • Combined with other tumors.
• • Patients had any serious coexisting medical conditions that could pose an unacceptable risk or negatively affect trial adherence. For example, unstable heart disease requiring treatment, chronic hepatitis, kidney disease, poor disease status, uncontrolled diabetes (fasting blood glucose \> 1.5 × ULN), and mental illness.
• • At the investigator's discretion, those who was not considered to be suitable for participation in the study.